These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 21683069

  • 1. 15-Deoxy-Δ12,14-prostaglandin J2 enhanced the anti-tumor activity of camptothecin against renal cell carcinoma independently of topoisomerase-II and PPARγ pathways.
    Yamamoto Y, Fujita M, Koma H, Yamamori M, Nakamura T, Okamura N, Yagami T.
    Biochem Biophys Res Commun; 2011 Jul 08; 410(3):563-7. PubMed ID: 21683069
    [Abstract] [Full Text] [Related]

  • 2. Cytotoxicity of 15-deoxy-Δ(12,14)-prostaglandin J(2) through PPARγ-independent pathway and the involvement of the JNK and Akt pathway in renal cell carcinoma.
    Fujita M, Tohji C, Honda Y, Yamamoto Y, Nakamura T, Yagami T, Yamamori M, Okamura N.
    Int J Med Sci; 2012 Jul 08; 9(7):555-66. PubMed ID: 22991494
    [Abstract] [Full Text] [Related]

  • 3. Histone deacetylase inhibitors and 15-deoxy-Delta12,14-prostaglandin J2 synergistically induce apoptosis.
    Koyama M, Izutani Y, Goda AE, Matsui TA, Horinaka M, Tomosugi M, Fujiwara J, Nakamura Y, Wakada M, Yogosawa S, Sowa Y, Sakai T.
    Clin Cancer Res; 2010 Apr 15; 16(8):2320-32. PubMed ID: 20371690
    [Abstract] [Full Text] [Related]

  • 4. The peroxisome proliferator-activated receptor gamma ligands, pioglitazone and 15-deoxy-Delta(12,14)-prostaglandin J(2), have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells.
    Shim J, Kim BH, Kim YI, Kim KY, Hwangbo Y, Jang JY, Dong SH, Kim HJ, Chang YW, Chang R.
    Int J Oncol; 2010 Jan 15; 36(1):223-31. PubMed ID: 19956851
    [Abstract] [Full Text] [Related]

  • 5. Involvement of c-jun N-terminal kinase activation in 15-deoxy-delta12,14-prostaglandin J2-and prostaglandin A1-induced apoptosis in AGS gastric epithelial cells.
    Liu JD, Lin SY, Ho YS, Pan S, Hung LF, Tsai SH, Lin JK, Liang YC.
    Mol Carcinog; 2003 May 15; 37(1):16-24. PubMed ID: 12720296
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of interleukin-1beta-induced cyclooxygenase 2 expression in human synovial fibroblasts by 15-deoxy-Delta12,14-prostaglandin J2 through a histone deacetylase-independent mechanism.
    Farrajota K, Cheng S, Martel-Pelletier J, Afif H, Pelletier JP, Li X, Ranger P, Fahmi H.
    Arthritis Rheum; 2005 Jan 15; 52(1):94-104. PubMed ID: 15641079
    [Abstract] [Full Text] [Related]

  • 7. 15d-PGJ2 induces apoptosis by reactive oxygen species-mediated inactivation of Akt in leukemia and colorectal cancer cells and shows in vivo antitumor activity.
    Shin SW, Seo CY, Han H, Han JY, Jeong JS, Kwak JY, Park JI.
    Clin Cancer Res; 2009 Sep 01; 15(17):5414-25. PubMed ID: 19690198
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Activation of peripheral kappa/delta opioid receptors mediates 15-deoxy-(Delta12,14)-prostaglandin J2 induced-antinociception in rat temporomandibular joint.
    Pena-dos-Santos DR, Severino FP, Pereira SA, Rodrigues DB, Cunha FQ, Vieira SM, Napimoga MH, Clemente-Napimoga JT.
    Neuroscience; 2009 Nov 10; 163(4):1211-9. PubMed ID: 19647045
    [Abstract] [Full Text] [Related]

  • 10. 15-Deoxy-Delta12,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors.
    Fulzele SV, Chatterjee A, Shaik MS, Jackson T, Ichite N, Singh M.
    Anticancer Drugs; 2007 Jan 10; 18(1):65-78. PubMed ID: 17159504
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Delta12,14-prostaglandin J2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receptor-gamma-independent mechanism.
    Grau R, Iñiguez MA, Fresno M.
    Cancer Res; 2004 Aug 01; 64(15):5162-71. PubMed ID: 15289320
    [Abstract] [Full Text] [Related]

  • 12. Suppression of chondrosarcoma cells by 15-deoxy-Delta 12,14-prostaglandin J2 is associated with altered expression of Bax/Bcl-xL and p21.
    Shen ZN, Nishida K, Doi H, Oohashi T, Hirohata S, Ozaki T, Yoshida A, Ninomiya Y, Inoue H.
    Biochem Biophys Res Commun; 2005 Mar 11; 328(2):375-82. PubMed ID: 15694358
    [Abstract] [Full Text] [Related]

  • 13. 15-Deoxy-Delta12,14-prostaglandin J2 inhibits angiotensin II-induced fibronectin expression via hepatocyte growth factor induction in human peritoneal mesothelial cells.
    Yokoyama Y, Masaki T, Kiribayashi K, Nakashima A, Kokoroishi K, Ogawa T, Kohno N, Yorioka N.
    Ther Apher Dial; 2010 Feb 11; 14(1):43-51. PubMed ID: 20438519
    [Abstract] [Full Text] [Related]

  • 14. The 15-deoxy-Delta12,14-prostaglandin J2 inhibits LPS-stimulated AKT and NF-kappaB activation and suppresses interleukin-6 in osteoblast-like cells MC3T3E-1.
    Jung WK, Park IS, Park SJ, Yea SS, Choi YH, Oh S, Park SG, Choi IW.
    Life Sci; 2009 Jul 03; 85(1-2):46-53. PubMed ID: 19409914
    [Abstract] [Full Text] [Related]

  • 15. The biphasic effects of cyclopentenone prostaglandins, prostaglandin J(2) and 15-deoxy-Delta(12,14)-prostaglandin J(2) on proliferation and apoptosis in rat basophilic leukemia (RBL-2H3) cells.
    Emi M, Maeyama K.
    Biochem Pharmacol; 2004 Apr 01; 67(7):1259-67. PubMed ID: 15013841
    [Abstract] [Full Text] [Related]

  • 16. Nanomolar and micromolar effects of 15-deoxy-delta 12,14-prostaglandin J2 on amnion-derived WISH epithelial cells: differential roles of peroxisome proliferator-activated receptors gamma and delta and nuclear factor kappa B.
    Berry EB, Keelan JA, Helliwell RJ, Gilmour RS, Mitchell MD.
    Mol Pharmacol; 2005 Jul 01; 68(1):169-78. PubMed ID: 15821150
    [Abstract] [Full Text] [Related]

  • 17. Ligands for peroxisome proliferator-activated receptor gamma have potent antitumor effect against human renal cell carcinoma.
    Yuan J, Takahashi A, Masumori N, Uchida K, Hisasue S, Kitamura H, Itoh N, Tsukamoto T.
    Urology; 2005 Mar 01; 65(3):594-9. PubMed ID: 15780399
    [Abstract] [Full Text] [Related]

  • 18. 15-Deoxy-Δ12,14-prostaglandin J2 Inhibits Cell Migration on Renal Cell Carcinoma via Down-Regulation of Focal Adhesion Kinase Signaling.
    Yamamoto Y, Koma H, Yagami T.
    Biol Pharm Bull; 2020 Mar 01; 43(1):153-157. PubMed ID: 31902920
    [Abstract] [Full Text] [Related]

  • 19. Protein thiol modification by 15-deoxy-Delta12,14-prostaglandin J2 addition in mesangial cells: role in the inhibition of pro-inflammatory genes.
    Sánchez-Gómez FJ, Cernuda-Morollón E, Stamatakis K, Pérez-Sala D.
    Mol Pharmacol; 2004 Nov 01; 66(5):1349-58. PubMed ID: 15317873
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.